Clinical Trial Update: EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluating EX02 CAR-T cells for relapsed and refractory acute myeloid leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• EX02 CAR-T Cells (EX02 CAR-T Cells)

Snippet

Sponsor: Zhimin Zhai | Conditions: Acute Myeloid Leukemia (AML), CAR-T | EARLY_Phase 1 | Status: RECRUITING